Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis

Eur J Clin Pharmacol. 1983;24(1):109-12. doi: 10.1007/BF00613936.

Abstract

The pharmacokinetics of cefroxadine was studied in 17 patients with terminal renal impairment, 10 of whom were undergoing 5 h dialysis sessions. The antibiotic was administered as a single oral dose of 500 mg. Cefroxadine followed a single compartment open kinetic model. During the interdialysis period in patients with terminal renal impairment, an average Cmax of 26.59 micrograms/ml and a tmax of 3.65 h were reached, which are greater than in patients with normal renal function. The serum half-life was reduced from 23.55 h in the interdialysis periods to 3.40 h during the dialysis sessions. The average extraction coefficient was 0.249. It is recommended that a 500 mg dose cefroxadine should be administered at the end of each dialysis session if the interdialysis period is 48 h.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cephalosporins / metabolism*
  • Cephradine / analogs & derivatives
  • Cephradine / metabolism*
  • Cephradine / therapeutic use
  • Female
  • Humans
  • Kidney Failure, Chronic / drug therapy
  • Kidney Failure, Chronic / metabolism*
  • Kinetics
  • Male
  • Middle Aged
  • Renal Dialysis

Substances

  • Cephalosporins
  • cefroxadine
  • Cephradine